Neumora Therapeutics Inc. (NASDAQ : NMRA) Stock

MWN-AI** Summary

MWN-AI** Analysis

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.

Description

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021.

Quote

Last:	$1.3076
Change Percent:	37.83%
Open:	$0.95005
Close:	$0.9487
High:	$1.31
Low:	$0.92
Volume:	12,435,643
Last Trade Date Time:	06/16/2026 12:45:49 pm

Stock Data

Market Cap:	$499,596,451
Float:	52,800,160
Insiders Ownership:	10.86%
Institutions:	30
Short Percent:	N/A
Industry:	Biotechnology & Life Sciences
Sector:	Healthcare
Website:	https://neumoratx.com
Country:	US
City:	Watertown